ArticleHeart rhythm2026
Disease penetrance and phenotypic spectrum of desmoplakin variant carriers in the population.
Article in Heart rhythm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- AssociatedDataset
Authors and funding
12 authors.
Funding
Abstract
backgroundDesmoplakin (DSP) variants cause arrhythmogenic cardiomyopathy, a disorder characterized by myocardial fibrosis, arrhythmias, and sudden cardiac death. DSP-mediated arrhythmogenic cardiomyopathy often involves left ventricular dysfunction and myocardial inflammation, yet existing diagnostic criteria may underdetect disease, underscoring the need for population-based penetrance estimates.
objectiveThis study aimed to assess the prevalence and phenotypic penetrance of DSP variants in a genotyped population.
methodsAmong 200,580 UK Biobank participants with exome sequencing, DSP variants were classified as predicted deleterious (pDel), predicted loss of function (pLOF), or ClinVar 2∗ pathogenic/likely pathogenic (P/LP). A subset of pDel carriers underwent electrocardiographic (ECG) and cardiac magnetic resonance testing, matched to genotype-negative controls. Phenotypic penetrance was assessed using the International Classification of Diseases, Tenth Revision, diagnoses, ECG, and cardiac magnetic resonance imaging. Variant clustering within functional DSP domains was also evaluated.
resultsOf 200,580 participants, 1407 (0.7%) carried a pDel, 168 (0.08%) a pLOF, and 44 (0.02%) a ClinVar 2∗ P/LP DSP variant. Myocarditis occurred in 0.28% of pDel, 1.8% of pLOF, and 4.5% of ClinVar P/LP carriers vs 0.07% of controls (P < .05). Cardiomyopathy prevalence increased from 1.4% (pDel) to 5.4% (pLOF) and 6.8% (P/LP) vs 0.6% in controls (P < .01). DSP carriers had more frequent lateral T-wave inversions and abnormal left ventricular strain. Missense variants clustered within 2 functional DSP domains.
conclusionDSP pDel variants are common but show low penetrance for myocarditis and cardiomyopathy, with risk increasing with more stringent classification. ECG and strain abnormalities may aid early detection, supporting genotype-first approaches for DSP interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.